loader image

Meet Our Team

Every breakthrough needs the right people behind it. We’re a focused team driven by the belief that our science can truly change lives.

Edo Kapetanovic, MD, PhD

Founder & CEO

Physician-scientist specializing in synthetic immunology and immuno-oncology. Primary scientific inventor of Encelta’s core innovation: decoupled TCR technology.

Oscar Irvin-Sellers

Chief Business Officer

Biotech executive with 25+ years’ experience in strategy, BD, and medical affairs. Expert in launching assets, scaling TCR therapies, and leading cross-functional biotech teams.

Joachim Koch, PhD

Chief Development Officer

Senior biotech executive with 20+ years in immunotherapy, leading IND-enabling programs, translational research, and clinical development of innovative antibody and cellular therapies.

Full Bio

Advisory Board

Thomas Wirth, M.Sc, PhD

Board Advisor

Biotech executive and entrepreneur with deep expertise in oncology-focused ATMPs, raising over $35M, and successfully driving multiple gene and cell therapies into clinical trials.

Sai T. Reddy, PhD

Co-Founder & Scientific Advisor

Leading expert in systems and synthetic immunology, pioneering immune-cell engineering for next-generation immunotherapies and personalized medicine.

Uwe Gottschalk

CMC Advisor

A seasoned biotech executive and investor with leadership roles at Lonza, Sartorius, and Bayer, now Operating Partner at Keensight Capital.

TPRO Cells: Engineered for Impact

Our TPRO cells are donor-derived T cells engineered to safely and selectively enhance the activity of T cell engagers without triggering graft-versus-host disease.

Explore Our Science

Menu

Our universal TPRO cells are engineered with one goal in mind: to enhance the therapeutic activity of T cell engagers (TCEs).

Social Media

Encelta AG 2025. All Rights Reserved.

Site by: Flyte.

Click here
Our Story
Our Team
Our Science
News & Media
Get in Touch

Check out our social media: